FMP
Cue Biopharma Shares Down 4%, Presents Data Updates From its Lead Programs
Nov 16, 2021(Last modified: Dec 19, 2023)
Cue Biopharma, Inc. (NASDAQ:CUE) shares closed more than 4% lower on Tuesday. Recently, the company presented data updates from its lead programs in the CUE-100 series, CUE-101 and CUE-102, at SITC. Analysts at Berenberg Bank believe the positive data provides strong support to CUE-101 and points to the potential of the entire platform. The analysts’ confidence in the outlook of CUE-101 for the treatment of HPV+ head/neck cancer is strong.
WACC vs ROIC: Evaluating Capital Efficiency and Value Creation
Introduction In corporate finance, assessing how effectively a company utilizes its capital is crucial. Two key metri...
BofA Sees AI Capex Boom in 2025, Backs Nvidia and Broadcom
Bank of America analysts reiterated a bullish outlook on data center and artificial intelligence capital expenditures fo...
Pinduoduo Inc. (PDD) Q1 2025 Earnings Report Analysis
Pinduoduo Inc., listed on the NASDAQ as PDD, is a prominent e-commerce platform in China, also operating internationally...
